Faculty of Science and Engineering, Manchester Institute of Biotechnology, University of Manchester, UK.
Discovery Biology, Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
FEBS Lett. 2018 Jul;592(14):2499-2511. doi: 10.1002/1873-3468.13170. Epub 2018 Jul 3.
Due in part to the needs of the biopharmaceutical industry, there has been an increased drive to generate high quality recombinant proteins in large amounts. However, achieving high yields can be a challenge as the novelty and increased complexity of new targets often makes them 'difficult-to-express'. This study aimed to define the molecular features that restrict the production of a model 'difficult-to-express' recombinant protein, Tissue Inhibitor Metalloproteinase-3 (TIMP-3). Building from experimental data, computational approaches were used to rationalize the redesign of this recombinant target to generate a chimera with enhanced secretion. The results highlight the importance of early identification of unfavourable sequence attributes, enabling the generation of engineered protein forms that bypass 'secretory' bottlenecks and result in efficient recombinant protein production.
由于生物制药行业的需求,人们越来越希望大量生成高质量的重组蛋白。然而,由于新靶标新颖性和复杂性的增加,使得它们往往“难以表达”,因此实现高产是一个挑战。本研究旨在确定限制模型“难以表达”重组蛋白组织抑制剂金属蛋白酶-3(TIMP-3)产生的分子特征。本研究从实验数据出发,利用计算方法对该重组靶标的重新设计进行合理化,以生成具有增强分泌能力的嵌合体。结果强调了早期识别不利序列属性的重要性,这使得能够生成可绕过“分泌”瓶颈的工程蛋白形式,从而有效生产重组蛋白。